References
- Barst RJ. Classification of pediatric pulmonary hypertensive vascular disease: Does it need to be different from the adult classification? Pulm Circ 2011;1:134-7
- Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis 1988;31:205-38
- Japan Intractable Diseases Information Center. 2014. http://www.nanbyou.or.jp/entry/1356#p09. Accessed March 3, 2017
- Montani D, Günther S, Dorfmüller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis 2013;8:1-28
- Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-D41
- Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119
- Pfizer Labs. Revatio® (sildenafil) tablets, for oral use [package insert]. 2012
- Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
- Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
- Galie N, Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J Am Coll Cardiol 2013;62:1101-2
- Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid 2015;10:99-109
- Sabri MR, Beheshtian E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol 2014;35:699-704
- Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012;33:683-8
- Shiva A, Shiran M, Rafati M, et al. Oral tadalafil in children with pulmonary arterial hypertension. Drug Res (Stuttg) 2016;66:7-10
- Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015;132:2037-99
- Yamazaki H, Kobayashi N, Taketsuna M, et al. Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension; Japan post-marketing surveillance data. Curr Med Res Opin 2017;33:1-22
- Kumano S. [GPSP: good post-marketing study practice]. Nihon Yakurigaku Zasshi 2012;140:81-4
- Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-7S
- Brown E. Medical Dictionary for Regulatory Activities (MedDRA). Pharmacovigilance. John Wiley & Sons, Ltd, NJ; 2006;168-83
- Eli Lilly and Company. Adcirca® (tadalafil) tablets for oral administration [package insert]. 2014
- Grunig E, Ohnesorge J, Benjamin N, et al. Plasma drug concentrations in patients with pulmonary arterial hypertension on combination treatment. Respiration 2017;94:26-37
- Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008;48:610-8